ERBB2 and neoplasm: Patients were accrued between September 2, 2020, and April 7, 2022, on the basis of the following tumor subtype distribution: HR+Her2+ (n = 16), HR+Her2- (n = 16), HR-Her2+ (n = 16) and HR-Her2- (n = 32).